Despite these promising findings, response to IVIG is not universal, particularly in advanced disease or in the presence of poor prognostic indicators such as underlying malignancy or myositis-specific autoantibodies, including anti-Ro52 antibodies as seen in this case [19,20]. Here, TRIM21 is linked to myositis disease.